EP4743435A1 - 4-HYDROXYBENOZOATE ESTERS FOR THE TREATMENT OF HPDL DEFICIENCY AND OTHER COQ10 HEAD GROUP SYNTHESIS DEFICIENCIES - Google Patents
4-HYDROXYBENOZOATE ESTERS FOR THE TREATMENT OF HPDL DEFICIENCY AND OTHER COQ10 HEAD GROUP SYNTHESIS DEFICIENCIESInfo
- Publication number
- EP4743435A1 EP4743435A1 EP24840539.1A EP24840539A EP4743435A1 EP 4743435 A1 EP4743435 A1 EP 4743435A1 EP 24840539 A EP24840539 A EP 24840539A EP 4743435 A1 EP4743435 A1 EP 4743435A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxybenozoate
- hpdl
- coq10
- deficiency
- esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363526421P | 2023-07-12 | 2023-07-12 | |
| US202463662587P | 2024-06-21 | 2024-06-21 | |
| PCT/US2024/037534 WO2025015136A1 (en) | 2023-07-12 | 2024-07-11 | 4-hydroxybenozate esters for treatment of hpdl deficiency and other deficiencies of coq10 headgroup synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4743435A1 true EP4743435A1 (en) | 2026-05-20 |
Family
ID=94216433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24840539.1A Pending EP4743435A1 (en) | 2023-07-12 | 2024-07-11 | 4-HYDROXYBENOZOATE ESTERS FOR THE TREATMENT OF HPDL DEFICIENCY AND OTHER COQ10 HEAD GROUP SYNTHESIS DEFICIENCIES |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4743435A1 (en) |
| AU (1) | AU2024294612A1 (en) |
| IL (1) | IL325742A (en) |
| WO (1) | WO2025015136A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159473A1 (en) | 2021-01-20 | 2022-07-28 | New York University | Methods and compositions for treating 4-hydroxyphenylpyruvate dioxygenase-like (hpdl)-related diseases or disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010047775A2 (en) * | 2008-10-20 | 2010-04-29 | Xenoport, Inc. | Methods of synthesizing a levodopa ester prodrug |
| JP7656340B2 (en) * | 2019-06-28 | 2025-04-03 | ダイナミック バイオロジクス インコーポレイテッド | Levodopa polymer conjugates, formulations thereof, and their use for the treatment of Parkinson's disease - Patents.com |
| WO2022159473A1 (en) * | 2021-01-20 | 2022-07-28 | New York University | Methods and compositions for treating 4-hydroxyphenylpyruvate dioxygenase-like (hpdl)-related diseases or disorders |
-
2024
- 2024-07-11 EP EP24840539.1A patent/EP4743435A1/en active Pending
- 2024-07-11 WO PCT/US2024/037534 patent/WO2025015136A1/en not_active Ceased
- 2024-07-11 IL IL325742A patent/IL325742A/en unknown
- 2024-07-11 AU AU2024294612A patent/AU2024294612A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024294612A1 (en) | 2026-01-22 |
| WO2025015136A1 (en) | 2025-01-16 |
| IL325742A (en) | 2026-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4043075C0 (en) | KN-93 FOR USE IN THE PREVENTION AND TREATMENT OF PSORIASIS | |
| EP4415755A4 (en) | ACE2-TARGETED COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19 | |
| EP3952840A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS | |
| EP4324927A4 (en) | Enzyme composition for the production of ?-nicotinamide mononucleotide and use thereof | |
| EP4203990A4 (en) | Methods and compositions for the treatment of glioblastoma | |
| EP4359405A4 (en) | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | |
| EP3920898C0 (en) | Methods and compositions for the treatment of sleep apnea | |
| EP4358991A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| EP4196127C0 (en) | NICOTINAMIDE MONONUCLEOIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF SICKLE CELL DISEASE | |
| EP4429763A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING AND HEMORRHOUSING DISORDERS | |
| EP4346811A4 (en) | Dual WNT signaling inhibition and AMPK activators for disease treatment | |
| EP4426322A4 (en) | MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISEASES | |
| EP4743003A1 (en) | OSTEOTOMY SYSTEMS AND PROCEDURES FOR THE TREATMENT OF MALFACIAL ALIGNMENT | |
| EP4446407A4 (en) | MANIPULATED MICROORGANISM FOR THE TREATMENT OF HYPERPHENYLALANINEMIA AND USE THEREOF | |
| EP4228696A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD DISORDERS | |
| EP4228661A4 (en) | COMPOSITIONS AND METHODS FOR PROMOTING THE GROWTH OF PERIPHERAL NERVE TISSUE | |
| EP4479060A4 (en) | 3ALPHA-OH-5BETA-PREGNAN-20-ONE COMPOSITIONS AND METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| EP4561557A4 (en) | Compositions and methods for the treatment of metabolic diseases | |
| EP4419127A4 (en) | BAG3 procedures and uses for the treatment of inflammation | |
| EP4415737A4 (en) | Compositions and methods for the treatment of skin diseases | |
| EP4422601A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| EP4422416A4 (en) | BUVINKONAS SP FOR USE IN THE PREVENTION AND TREATMENT OF DISEASES | |
| EP4340835A4 (en) | Methods and compositions for the treatment of cardiovascular diseases | |
| EP4408532A4 (en) | Compositions and methods for the treatment of PCDH19-related diseases | |
| EP4395894A4 (en) | METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |